286 related articles for article (PubMed ID: 24713141)
1. Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.
Hayashi S; Kurata N; Yamaguchi A; Amagase K; Takeuchi K
J Pharmacol Exp Ther; 2014 Jun; 349(3):470-9. PubMed ID: 24713141
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet, a calcimimetic, prevents nonsteroidal antiinflammatory drug-induced small intestinal damage in rats.
Hayashi S; Kurata N; Kitahirachi E; Nishimura Y; Amagase K; Yano T; Takeuchi K
J Physiol Pharmacol; 2013 Aug; 64(4):453-63. PubMed ID: 24101391
[TBL] [Abstract][Full Text] [Related]
3. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events.
Tanaka A; Hase S; Miyazawa T; Ohno R; Takeuchi K
J Pharmacol Exp Ther; 2002 Dec; 303(3):1248-54. PubMed ID: 12438549
[TBL] [Abstract][Full Text] [Related]
4. Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs.
Takeuchi K; Yokota A; Tanaka A; Takahira Y
Dig Dis Sci; 2006 Jul; 51(7):1250-9. PubMed ID: 16944022
[TBL] [Abstract][Full Text] [Related]
5. 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors.
Kunikata T; Tanaka A; Miyazawa T; Kato S; Takeuchi K
Dig Dis Sci; 2002 Apr; 47(4):894-904. PubMed ID: 11991626
[TBL] [Abstract][Full Text] [Related]
6. Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors.
Takeuchi K; Tanigami M; Amagase K; Ochi A; Okuda S; Hatazawa R
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S67-74. PubMed ID: 20586869
[TBL] [Abstract][Full Text] [Related]
7. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
Bijvelds MJ; Bot AG; Escher JC; De Jonge HR
Gastroenterology; 2009 Sep; 137(3):976-85. PubMed ID: 19454284
[TBL] [Abstract][Full Text] [Related]
8. Intestinal protection by lafutidine, a histamine H(2)-receptor antagonist, against indomethacin-induced damage in rats--role of endogenous nitric oxide.
Tanaka A; Mizoguchi H; Hase S; Miyazawa T; Takeuchi K
Med Sci Monit; 2001; 7(5):869-77. PubMed ID: 11535926
[TBL] [Abstract][Full Text] [Related]
9. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.
Jakab RL; Collaco AM; Ameen NA
Dig Dis Sci; 2012 Nov; 57(11):2826-45. PubMed ID: 22923315
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.
Konaka A; Nishijima M; Tanaka A; Kunikata T; Kato S; Takeuchi K
J Physiol Pharmacol; 1999 Mar; 50(1):25-38. PubMed ID: 10210152
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/cGMP-dependent mechanism.
Kato N; Mashita Y; Kato S; Mitsufuji S; Yoshikawa T; Takeuchi K
Dig Dis Sci; 2009 Nov; 54(11):2346-56. PubMed ID: 19101800
[TBL] [Abstract][Full Text] [Related]
12. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.
Moeser AJ; Nighot PK; Engelke KJ; Ueno R; Blikslager AT
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G647-56. PubMed ID: 17053162
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Amagase K; Ochi A; Sugihara T; Kato S; Takeuchi K
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S111-8. PubMed ID: 20586851
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats.
Takeuchi K; Miyazawa T; Tanaka A; Kato S; Kunikata T
Digestion; 2002; 66(1):30-41. PubMed ID: 12379813
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effects of prostaglandin E2 on NSAID-induced enteropathy-role of EP4 receptors in its protective and healing-promoting effects.
Takeuchi K
Curr Opin Pharmacol; 2014 Dec; 19():38-45. PubMed ID: 25063918
[TBL] [Abstract][Full Text] [Related]
16. Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility.
Satoh H; Amagase K; Takeuchi K
J Pharmacol Exp Ther; 2012 Nov; 343(2):270-7. PubMed ID: 22854201
[TBL] [Abstract][Full Text] [Related]
17. Influence of Adrenalectomy on Protective Effects of Urocortin I, a Corticotropin-Releasing Factor, Against Indomethacin-Induced Enteropathy in Rats.
Takeuchi K; Abe N; Kumano A
Curr Neuropharmacol; 2016; 14(8):866-875. PubMed ID: 27397599
[TBL] [Abstract][Full Text] [Related]
18. Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
Norimatsu Y; Moran AR; MacDonald KD
Biochem Biophys Res Commun; 2012 Sep; 426(3):374-9. PubMed ID: 22960173
[TBL] [Abstract][Full Text] [Related]
19. Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats.
Tanaka A; Kunikata T; Mizoguchi H; Kato S; Takeuchi K
J Physiol Pharmacol; 1999 Sep; 50(3):405-17. PubMed ID: 10574470
[TBL] [Abstract][Full Text] [Related]
20. Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: relation to intestinal hypermotility.
Tanaka A; Matsumoto M; Hayashi Y; Takeuchi K
J Gastroenterol Hepatol; 2005 Jan; 20(1):38-45. PubMed ID: 15610444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
